Your browser doesn't support javascript.
loading
Research progress of antithrombotic therapy after transcatheter aortic valve implantation / 中国胸心血管外科临床杂志
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery ; (12): 710-715, 2020.
Article Dans Chinois | WPRIM | ID: wpr-822575
ABSTRACT
@#Traditional surgical aortic valve replacement is associated with a high risk of serious complications, especially in elderly patients with other preoperative diseases and unable to undergo thoracotomy. Therefore, transcatheter aortic valve implantation (TAVI) is now the accepted standard treatment for patients with symptomatic severe aortic stenosis at elevated risk for conventional surgical valve replacement. Currently, guidelines propose the use of dual antiplatelet therapy for the prevention of thromboembolic events after TAVI in the patients without an indication for oral anticoagulation. While, this strategy is empiric and largely based on expert consensus extrapolated from the arena of percutaneous coronary intervention. Antithrombotic therapy is associated with a significant occurrence of both thrombotic and bleeding complications, thus, the balance between thrombotic and bleeding risk is critical. This review summarizes current guidelines and the evidence underpinning them and explores the rational for using antiplatelet and/or anticoagulant strategies after TAVI.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Guide de pratique langue: Chinois Texte intégral: Chinese Journal of Clinical Thoracic and Cardiovascular Surgery Année: 2020 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Guide de pratique langue: Chinois Texte intégral: Chinese Journal of Clinical Thoracic and Cardiovascular Surgery Année: 2020 Type: Article